IMGN announced a shortened path to approval of IMGN653 this morning, it's a much smaller trial that the FDA has agreed upon that could conclude in first half of 2021. Roughly a year or more is trimmed from the time which is needed for the Merisol Trial which will be underway shortly as well. Clearly the market liked this today.

I believe this may be what expedite a partnership for the drug, I'm just hoping IMGN sticks to its guns and keeps the U.S. for itself.

Gary